Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in drugmaker

AstraZeneca Wins Two Approval Recommendations From EU Agency

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approving Forxiga for treating a form of heart failure and Trixeo Aerosphere for a form of lung disorder known as "smoker's lung".

Read More

J&J To Contribute Up To $5 Billion To Potential US Opioid Settlement

That proposal also called for the drug distributors McKesson Corp, Cardinal Health and AmerisourceBergen to pay a combined $18 billion, but the framework met resistance from some states and local governments.

Read More

J&J Pauses COVID-19 Vaccine Trials Due To Unexplained Illness In Participant

J&J's move follows a similar one by AstraZeneca Plc. In September, AstraZeneca paused late-stage trials of its experimental coronavirus vaccine, developed with the University of Oxford, due to an unexplained illness in a UK study participant.

Read More

South Korea's Celltrion Gets Approval For Phase 3 Trials Of COVID-19 Antibody Drug

The Ministry of Food and Drug Safety recently approved a Phase 2/3 study on patients with mild and moderate cases of COVID-19, Lee Sang-joon, Celltrion's senior executive vice president

Read More

Eli Lilly In Deal To Supply COVID-19 Drugs To Low-Income Countries

Lilly had previously said it would make one million doses of its single antibody treatment available by the end of the year, and another 50,000 doses of its dual-antibody therapy by the fourth quarter this year.

Read More

China Joins COVAX Initiative For COVID-19 Vaccine Distribution

Chinese foreign ministry's Hua also said in Friday's statement that China has ample COVID-19 vaccine manufacturing capabilities and will prioritise supplying developing countries when vaccines are ready.

Read More

Gilead's Remdesivir Shaved Five Days Off COVID-19 Recovery Time, Reduced Risk Of Death In Some

Gilead's drug was among the first to be used as a treatment for the novel coronavirus, and was one of the drugs recently used to treat U.S. President Donald Trump.

Read More

EU Agency Recommends AstraZeneca-Merck Drug Lynparza For Two Cancers

Prostate cancer is the second-most common type of cancer in men worldwide, while ovarian cancer is the fifth most common cause of cancer death in Europe.

Read More

BioNTech CEO Expects Vaccine Can Be Fridge-Stored For Two Weeks

A good vaccine should have an efficacy of at least 70% to 75% for it to quell the pandemic and that was also the yardstick that BioNTech had set itself.

Read More

Pfizer Says Late-Stage Coronavirus Vaccine Study Shows Moderate Side Effects

The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech.

Read More

Gilead To Buy Cancer Drugmaker Immunomedics For $21 Billion

Gilead's offer will be funded with $15 billion in cash on hand, and through $6 billion in newly issued debt, according to the drugmaker.

Read More

Vaccine Hopes Boost World Share Markets

Drugmaker AstraZeneca said at the weekend it has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs.

Read More

Gilead To Buy Cancer Drugmaker Immunomedics For $21 Billion

The offer will be funded with $15 billion in cash on hand, and through $6 billion in newly issued debt, according to the drugmaker.

Read More

Serum Institute Puts India Trials Of AstraZeneca's COVID-19 Vaccine On Hold

AstraZeneca said on Tuesday it had paused trials of its experimental coronavirus vaccine because of an unexplained illness in a study participant

Read More

AstraZeneca Pauses Coronavirus Vaccine Trial As Participant Illness Investigated

Germany's Leukocare, which is working on a vaccine similar to AstraZeneca's but at an earlier stage, agreed that safety issues are likely to crop up in large trials.

Read More